Dermata Therapeutics Stock Today

DRMA Stock  USD 2.47  0.20  7.49%   


0 of 100

Very Weak

Odds Of Distress

Over 85

Very High
Dermata Therapeutics is trading at 2.47 as of the 25th of July 2024, a 7.49 percent decrease since the beginning of the trading day. The stock's open price was 2.67. Dermata Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Dermata Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of June 2024 and ending today, the 25th of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
13th of August 2021
Health Care
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company was incorporated in 2014 and is headquartered in San Diego, California. The company has 693.17 K outstanding shares of which 21.83 K shares are currently shorted by private and institutional investors with about 0.4 trading days to cover. More on Dermata Therapeutics

Moving together with Dermata Stock

  0.87CANB Can B CorpPairCorr
  0.67PME Pingtan Marine EnterprisePairCorr

Moving against Dermata Stock

  0.95WMT Walmart Sell-off TrendPairCorr
  0.87T ATT Inc Buyout TrendPairCorr
  0.85MACAU Moringa Acquisition CorpPairCorr
  0.84BAC Bank of America Fiscal Year End 10th of January 2025 PairCorr
  0.83AIBBU AIB Acquisition CorpPairCorr
  0.75MMM 3M Company Fiscal Year End 28th of January 2025 PairCorr

Dermata Stock Highlights

ESG Sustainability
Thematic IdeaPharmaceutical Products (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Jakarta Stock Exchange, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities1.5 M1.6 M
Notably Down
Very volatile
Non Current Liabilities Total795.5 M757.6 M
Sufficiently Up
Slightly volatile
Total Assets6.4 MM
Significantly Down
Slightly volatile
Total Current Assets6.4 MM
Significantly Down
Slightly volatile
Debt Levels
Dermata Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Dermata Therapeutics' financial leverage. It provides some insight into what part of Dermata Therapeutics' total assets is financed by creditors.
Dermata Therapeutics currently holds 1.62 M in liabilities. Dermata Therapeutics has a current ratio of 7.91, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Dermata Therapeutics' use of debt, we should always consider it together with its cash and equity.

Change In Cash

1 Million
Dermata Therapeutics (DRMA) is traded on NASDAQ Exchange in USA. It is located in 3525 Del Mar Heights Road, San Diego, CA, United States, 92130 and employs 8 people. Dermata Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 901.13 K. Dermata Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 693.17 K outstanding shares of which 21.83 K shares are currently shorted by private and institutional investors with about 0.4 trading days to cover. Dermata Therapeutics currently holds about 10.63 M in cash with (6.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.05.
Check Dermata Therapeutics Probability Of Bankruptcy
Ownership Allocation
Roughly 96.0 percent of Dermata Therapeutics outstanding shares are held by general public with 2.46 (percent) owned by insiders and only 1.74 % by other corporate entities.
Check Dermata Ownership Details

Dermata Stock Institutional Holders

InstituionRecorded OnShares
Two Sigma Securities, Llc2024-03-31
20 K
Acadian Asset Management Llc2024-03-31
19.3 K
Geode Capital Management, Llc2024-03-31
12.2 K
Tower Research Capital Llc2023-12-31
6.4 K
Wells Fargo & Co2024-03-31
Northwestern Mutual Wealth Management Co2024-03-31
Armistice Capital, Llc2024-03-31
Virtu Financial Llc2024-03-31
Ubs Group Ag2023-12-31
View Dermata Therapeutics Diagnostics

Dermata Therapeutics Historical Income Statement

At present, Dermata Therapeutics' Net Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Depreciation And Amortization is expected to grow to about 8.4 M, whereas Selling General Administrative is forecasted to decline to about 3.5 M. View More Fundamentals

Dermata Stock Against Markets

Dermata Therapeutics Corporate Management

Maria MBASenior AssuranceProfile
Gerald ProehlPresident, FounderProfile
Sean ProehlSenior DevelopmentProfile
David HaleCoFounder DirectorProfile
Dr MPHSenior OfficerProfile

Additional Information and Resources on Investing in Dermata Stock

When determining whether Dermata Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dermata Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dermata Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dermata Therapeutics Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dermata Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. If investors know Dermata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dermata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Return On Assets
Return On Equity
The market value of Dermata Therapeutics is measured differently than its book value, which is the value of Dermata that is recorded on the company's balance sheet. Investors also form their own opinion of Dermata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dermata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dermata Therapeutics' market value can be influenced by many factors that don't directly affect Dermata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dermata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dermata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.